ABUS יחס מהיר Arbutus Biopharma

Arbutus Biopharma (ABUS) is a biopharmaceutical player developing hepatitis B therapies and possessing valuable LNP technologies. This daily price action reflects a quick ratio of 79.80. Patents for drug delivery methods ensure a high barrier to entry. However, the company's capital is under pressure due to mRNA litigation and uncertainty regarding the outcome of current clinical trials.

The long-term sustainability of Arbutus Biopharma (ABUS) depends on its ability to cover short-term liabilities excluding slow-moving inventories, which is reflected in the quick ratio through the sum of cash and accounts receivable. High values for this metric guarantee the financial autonomy necessary to implement costly clinical trials for antiviral programs and to enter into strategic alliances with global pharmaceutical behemoths.